04:37 PM EDT, 10/03/2024 (MT Newswires) -- Abivax ( ABVX ) said Thursday it enrolled the first patient in a phase 2b trial evaluating obefazimod as a once-daily treatment option for adults with moderately to severely active Crohn's disease.

The multicenter, double-blind, randomized, placebo-controlled trial will assess the efficacy and safety of the drug candidate compared to placebo, it said.